Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Parcel Pick Up
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Panbela Therapeutics, Inc.
< Previous
1
2
Next >
Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi
September 05, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference
August 28, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101
August 14, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela to Host Second Quarter 2023 Earnings Conference Call on August 10, 2023
July 31, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Opens Enrollment in UK and Germany for Aspire Trial in Pancreatic Cancer, All Countries/Regions in the Aspire Trial are Now Open and Actively Enrolling
July 24, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds
July 19, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Issuance of New Patent in Australia Patent is for Claims of a Novel Process for the Production of SBP-101
July 17, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Preliminary Safety Analysis for ASPIRE Trial
July 10, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis
June 28, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Poster Presentation at the Endocrine Society Meeting: Polyamine Inhibition and β-Cell Preservation in Recent Onset Type 1 Diabetes
June 26, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Closing of Approximately $8.5 Million Public Offering
June 21, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Pricing of Approximately $8.5 Million Public Offering
June 16, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Sponsored Research Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy
June 13, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Poster Presentation at Immunology of Diabetes Society Meeting: Evaluating the Potential of CPP-1X (Eflornithine) in Recent Onset Type 1 Diabetes
June 01, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces 1-for-30 Reverse Stock Split Effective June 1, 2023
May 31, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Clinical Trial with Moffitt Cancer Center for Phase I/II Program in STK11 Mutant Non-Small Cell Lung Cancer
May 22, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023
April 24, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Poster Presentation at American Association for Cancer Research: Evaluating the potential of spermine analogue ivospemin (SBP-101) in combination with chemotherapy in ovarian cancer
April 19, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
First Patient Enrolled in JDRF-Funded Phase II Trial of CPP-1X-T for Recent Onset Type I Diabetes, Led by Indiana University School of Medicine
April 12, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Regains Worldwide Rights to Develop and Commercialize FlynpoviTM in Patients with Familial Adenomatous Polyposis (FAP)
April 11, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Immunology of Diabetes Society Meeting
April 10, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Endocrine Society Meeting
April 06, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine
April 03, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Issuance of New Patent in Japan; Patent is for Claims of a Novel Process for the Production of SBP-101
March 22, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela to Host Fourth Quarter and Year End 2022 Earnings Conference Call on March 16, 2023
March 08, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces First Patient Enrolled in South Korea for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
March 07, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)
March 01, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Closing of Approximately $15 Million Public Offering, and Regains Compliance with Nasdaq Listing Standards
February 13, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Pricing of Approximately $15 Million Public Offering
January 26, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
Panbela Announces Adoption of Commission Implementing Decision from the EMA for the Orphan Designation of Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
January 19, 2023
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Tickers
PBLA
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.